Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers aged 18 to 65 years inclusive~* Body mass index (BMI) between 18 and 30 kg/m2 inclusive.~* Have no contraindications from the following: a detailed medical and surgical history, and a complete physical examination~* Able to participate, and willing to give written informed consent and to comply with the study restrictions~Exclusion Criteria:~* History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, mental, cardiac, vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis.~* History of alcohol and/or drug abuse or addiction within the last 2 years prior to Day 1 of the study.~* Consumption of nicotine and/or tobacco containing products within the last 3 months prior to Day 1 of the study.~* Infection with human immunodeficiency virus, hepatitis B and/or hepatitis C~* Any condition or disease detected during the medical interview / physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.~* Positive drug screen or alcohol test at screening or prior to enrollment.~* Coffee or tea consumption \> 10 cups per day or methylxanthine containing drinks \>1.5 liter/day or more than 250 g/day of chocolate.~* Alcohol consumption averaging \> 3 drinks daily

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: PLACEBO_COMPARATOR): None
- Treatment D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).